The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations.
作者信息
Krismer Florian, Palma Jose-Alberto, Calandra-Buonaura Giovanna, Stankovic Iva, Vignatelli Luca, Berger Anna-Karin, Falup-Pecurariu Cristian, Foubert-Samier Alexandra, Höglinger Günter, Kaufmann Horacio, Kellerman Larry, Kim Han-Joon, Klockgether Thomas, Levin Johannes, Martinez-Martin Pablo, Mestre Tiago A, Pellecchia Maria Teresa, Perlman Susan, Qureshi Irfan, Rascol Olivier, Schrag Anette, Seppi Klaus, Shang Huifang, Stebbins Glenn T, Wenning Gregor K, Singer Wolfgang, Meissner Wassilios G
机构信息
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
出版信息
Mov Disord. 2022 Dec;37(12):2336-2341. doi: 10.1002/mds.29215. Epub 2022 Sep 8.
Abstract
摘要
相似文献
1
The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations.统一多系统萎缩评定量表：现状、批评与建议。
Mov Disord. 2022 Dec;37(12):2336-2341. doi: 10.1002/mds.29215. Epub 2022 Sep 8.
2
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).统一多系统萎缩评定量表（UMSARS）的开发与验证
Mov Disord. 2004 Dec;19(12):1391-402. doi: 10.1002/mds.20255.
3
Assessment of quality of life with the multiple system atrophy health-related quality of life scale.使用多系统萎缩相关生活质量量表评估生活质量。
Mov Disord. 2012 Oct;27(12):1574-7. doi: 10.1002/mds.25174. Epub 2012 Oct 2.
4
Comparison of Different Symptom Assessment Scales for Multiple System Atrophy.多系统萎缩不同症状评估量表的比较
Cerebellum. 2016 Apr;15(2):190-200. doi: 10.1007/s12311-015-0686-4.
5
The international cooperative ataxia rating scale in Machado-Joseph disease. Comparison with the unified multiple system atrophy rating scale.马查多-约瑟夫病的国际合作共济失调评定量表。与统一多系统萎缩评定量表的比较。
Mov Disord. 2007 Oct 15;22(13):1976-9. doi: 10.1002/mds.21735.
6
An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale.统一多系统萎缩评定量表的项目反应理论分析。
Parkinsonism Relat Disord. 2022 Jan;94:40-44. doi: 10.1016/j.parkreldis.2021.11.024. Epub 2021 Nov 30.
7
Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure.多系统萎缩与帕金森病的前瞻性鉴别，伴或不伴自主神经功能衰竭。
Arch Neurol. 2009 Jun;66(6):742-50. doi: 10.1001/archneurol.2009.71.
8
Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.多系统萎缩中的帕金森综合征：与帕金森病相比的自然史、严重程度（统一帕金森病评定量表第三部分）及残疾评估
Mov Disord. 2002 Jul;17(4):701-9. doi: 10.1002/mds.10171.
9
Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time.Scopa-Aut 问卷在多系统萎缩中的评估：与 UMSARS 评分的关系及随时间的进展。
Parkinsonism Relat Disord. 2012 Jun;18(5):612-5. doi: 10.1016/j.parkreldis.2011.12.009. Epub 2012 Jan 9.
10
Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement.统一多系统萎缩评分量表作为临床试验结局指标的局限性及改进路线图。
Clin Auton Res. 2021 Apr;31(2):157-164. doi: 10.1007/s10286-021-00782-w. Epub 2021 Feb 7.
引用本文的文献
1
Cardiovascular autonomic failure correlates with cutaneous autonomic denervation in PD and MSA.心血管自主神经功能衰竭与帕金森病（PD）和多系统萎缩（MSA）中的皮肤自主神经去神经支配相关。
Clin Auton Res. 2025 Sep 12. doi: 10.1007/s10286-025-01154-4.
2
Peripheral Inflammation Profile of Cerebellar Ataxia.小脑共济失调的外周炎症特征
Curr Neuropharmacol. 2025;23(10):1276-1286. doi: 10.2174/011570159X379620250225075810.
3
Early onset sleep disorders predict severity, progression and death in multiple system atrophy.早发性睡眠障碍可预测多系统萎缩的严重程度、病情进展及死亡情况。
J Neurol. 2025 Mar 1;272(3):239. doi: 10.1007/s00415-025-12969-6.
4
Clinical comparison of the 2008 and 2022 diagnostic criteria for early multiple system atrophy-cerebellar type.2008年与2022年早期多系统萎缩-小脑型诊断标准的临床比较
Clin Auton Res. 2024 Dec;34(6):609-611. doi: 10.1007/s10286-024-01061-0. Epub 2024 Sep 11.
5
Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research.弥合统计学显著性与临床相关性之间的差距：运动障碍研究中报告的量表最小临床重要差异（MCID）阈值的系统评价
Heliyon. 2024 Feb 20;10(5):e26479. doi: 10.1016/j.heliyon.2024.e26479. eCollection 2024 Mar 15.
6
Time-resolved quantification of fine hand movements as a proxy for evaluating bradykinesia-induced motor dysfunction.作为评估运动迟缓引起的运动功能障碍的替代指标，对手部精细运动的时间分辨定量分析。
Sci Rep. 2024 Mar 4;14(1):5340. doi: 10.1038/s41598-024-55862-4.
7
Recent Advances in Clinical Trials in Multiple System Atrophy.多系统萎缩症临床试验的最新进展。
Curr Neurol Neurosci Rep. 2024 Apr;24(4):95-112. doi: 10.1007/s11910-024-01335-0. Epub 2024 Feb 28.
8
Impulse Control Disorders in Parkinson's Disease and Atypical Parkinsonian Syndromes-Is There a Difference?帕金森病和非典型帕金森综合征中的冲动控制障碍——有区别吗？
Brain Sci. 2024 Feb 16;14(2):181. doi: 10.3390/brainsci14020181.
9
Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers.多系统萎缩的诊断：当前临床指南与新兴分子生物标志物
Front Neurol. 2023 Sep 29;14:1210220. doi: 10.3389/fneur.2023.1210220. eCollection 2023.
10
Tackling the usefulness of neurofilament light chain in multiple system atrophy: diagnostic and prognostic perspectives.探讨神经丝轻链在多系统萎缩中的应用价值：诊断与预后视角
Clin Auton Res. 2023 Dec;33(6):617-618. doi: 10.1007/s10286-023-00992-4. Epub 2023 Oct 14.
本文引用的文献
1
Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis.统一多系统萎缩评定量表项目的变化敏感性和以患者为中心：基于数据的分析。
Mov Disord. 2022 Jul;37(7):1425-1431. doi: 10.1002/mds.28993. Epub 2022 Mar 25.
2
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.西罗莫司抑制mTOR在多系统萎缩中的应用：一项随机、双盲、安慰剂对照的无效性试验及1年生物标志物纵向分析。
Mov Disord. 2022 Apr;37(4):778-789. doi: 10.1002/mds.28923. Epub 2022 Jan 18.
3
An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale.统一多系统萎缩评定量表的项目反应理论分析。
Parkinsonism Relat Disord. 2022 Jan;94:40-44. doi: 10.1016/j.parkreldis.2021.11.024. Epub 2021 Nov 30.
4
Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement.统一多系统萎缩评分量表作为临床试验结局指标的局限性及改进路线图。
Clin Auton Res. 2021 Apr;31(2):157-164. doi: 10.1007/s10286-021-00782-w. Epub 2021 Feb 7.
5
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.一项特定的α-突触核蛋白免疫疗法 PD01A 和 PD03A 治疗多系统萎缩的 1 期随机试验。
Mov Disord. 2020 Nov;35(11):1957-1965. doi: 10.1002/mds.28218. Epub 2020 Sep 3.
6
Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders.2019年冠状病毒病大流行对帕金森病和运动障碍的影响
Mov Disord. 2020 May;35(5):711-715. doi: 10.1002/mds.28067. Epub 2020 Apr 16.
7
Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study.多系统萎缩的疾病进展和预后因素：一项前瞻性队列研究。
Neurobiol Dis. 2020 Jun;139:104813. doi: 10.1016/j.nbd.2020.104813. Epub 2020 Feb 20.
8
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.没食子酸表没食子儿茶素酯在多系统萎缩症（PROMESA）中的安全性和疗效：一项随机、双盲、安慰剂对照试验。
Lancet Neurol. 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3. Epub 2019 Jul 2.
9
Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy.鞘内注射自体间充质干细胞治疗多系统萎缩。
Neurology. 2019 Jul 2;93(1):e77-e87. doi: 10.1212/WNL.0000000000007720. Epub 2019 May 31.
10
Factors associated with deterioration of health-related quality of life in multiple system atrophy: 1-year follow-up study.多系统萎缩中与健康相关生活质量恶化相关的因素：1年随访研究。
Acta Neurol Belg. 2018 Dec;118(4):589-595. doi: 10.1007/s13760-018-0962-4. Epub 2018 Jun 11.
Zotero 插件